Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics Plc (BRNS)
:BRNS
Vtp-1000
Celiac Disease
Early Phase I
Recruiting
VTP-1000 in Adults With Celiac Disease
Feb 16, 2024
―
Chadox1-Pcaq, Mva-Pcaq
Prostate Cancer
Phase I/II
Terminated
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Nov 01, 2022
―
Nivolumab, Chadox1-Hbv, Mva-Hbv
Chronic Hepatitis B
Phase II
Active Not Recruiting
Efficacy of VTP-300 in Chronic Hepatitis B Infection
Apr 12, 2022
―
Chadox1-Hpv, Mva-Hpv
Hpv Infection, Cin1
Phase I/II
Completed
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
Oct 22, 2020
―
Chadox1-Hbv
Healthy, Hepatitis B
Phase I
Completed
First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection
Feb 28, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Barinthus Biotherapeutics Plc (BRNS) have in its pipeline
BRNS is currently developing the following drugs: Vtp-1000, Chadox1-Pcaq, Mva-Pcaq, Nivolumab, Chadox1-Hbv, Mva-Hbv. These drug candidates are in various stages of clinical development as the company works toward FDA approval.